Abstract: The purpose of the present invention is to provide a novel medical application using pluripotent stem cells in regenerative medicine. The present invention provides a cell formulation and pharmaceutical composition that are for amelioration and therapy for frequent urination and bladder pain caused by the inflammation of the bladder and that contain SSEA-3 positive pluripotent stem cells isolated from cultured mesenchymal cells or a mesenchymal tissue of a living organism. The cell formulation according to the present invention is considered to be based on a mechanism in which, for example, Muse cells are administered against interstitial cystitis having the abovementioned disorders to be successfully engrafted into affected bladder tissue, whereby the disorders are ameliorated and treated.

Abstract: Provided is an overtube assembly including an overtube having an adjustable length. The overtube assembly has the overtube and a mouthpiece. The overtube has a plurality of recesses (e.g., grooves) on the outer circumference thereof. The mouthpiece has a locking portion (e.g., a protrusion or ridge) that is locked to the recesses. The mouthpiece can move between a locking position at which the locking portion engages with the recess and an unlocking position at which the locking portion does not engage with the recess.

Abstract: Disclosed is an isolated monoclonal antibody against a human Transforming Growth Factor-? (TGF-?) Latency Associated Protein (LAP) degradate, the isolated monoclonal antibody being capable of recognizing an integrin binding site in the human TGF-? LAP degradate.

Abstract: A method for producing a new deafness model animal and a new deafness model animal produced by the method, enabling research that can also be applied to clinical application to a human. The present invention provides a method for producing an acoustic trauma deafness model animal, the method including exposing a non-human primate animal to a sound having a frequency of 1 kHz to 32 kHz and a sound pressure level of 100 dB to 150 dB for 10 minutes to 360 minutes. In addition, the present invention provides an acoustic trauma deafness model animal provided by the method for producing an acoustic trauma deafness model animal.

Abstract: For human liver cancer cell lines which have been found to extracellularly release PKC?, an analysis of neutralization of the action of PKC? was carried out using a monoclonal antibody against PKC?. As a result, it was found that anti-PKC? antibody or an antigen-binding fragment thereof has a cell growth-inhibiting effect on the liver cancer cell lines.

Abstract: A novel vaccine that can induce sufficiently high cell-mediated immunity is disclosed. The vaccine of the present invention contains, as an effective component, a polypeptide comprising a tandem repeat structure in which an MHC class I epitope region derived from an antigen protein and a spacer sequence are linked to each other alternately and repeatedly at least three times, or a recombinant vector which comprises a polynucleotide encoding said polypeptide and is capable of expressing said polypeptide in vivo. The spacer sequence is, for example, a sequence generated as an amino acid sequence inevitably encoded by a single base sequence which is designed such that the MHC class I epitope region derived from the antigen protein, an MHC class II epitope region derived from the antigen protein, and at least one higher-order-structure-stabilizing region are encoded by different reading frames in said single base sequence.

Abstract: A novel vaccine that can induce sufficiently high cell-mediated immunity is disclosed. The vaccine of the present invention contains, as an effective component, a polypeptide comprising a tandem repeat structure in which an MHC class I epitope region derived from an antigen protein and a spacer sequence are linked to each other alternately and repeatedly at least three times, or a recombinant vector which comprises a polynucleotide encoding said polypeptide and is capable of expressing said polypeptide in vivo. The spacer sequence is, for example, a sequence generated as an amino acid sequence inevitably encoded by a single base sequence which is designed such that the MHC class I epitope region derived from the antigen protein, an MHC class II epitope region derived from the antigen protein, and at least one higher-order-structure-stabilizing region are encoded by different reading frames in said single base sequence.

Abstract: A novel vaccine that can induce sufficiently high cell-mediated immunity is disclosed. The vaccine of the present invention contains, as an effective component, a polypeptide comprising a tandem repeat structure in which an MHC class I epitope region derived from an antigen protein and a spacer sequence are linked to each other alternately and repeatedly at least three times, or a recombinant vector which comprises a polynucleotide encoding said polypeptide and is capable of expressing said polypeptide in vivo. The spacer sequence is, for example, a sequence generated as an amino acid sequence inevitably encoded by a single base sequence which is designed such that the MHC class I epitope region derived from the antigen protein, an MHC class II epitope region derived from the antigen protein, and at least one higher-order-structure-stabilizing region are encoded by different reading frames in said single base sequence.

Abstract: Disclosed is an isolated monoclonal antibody against a human TGF-? LAP degradate, the isolated monoclonal being capable of recognizing an integrin binding site in the human TGF-? LAP degradate.

Abstract: Disclosed herein is a radioactive cesium decontaminator, a method of producing a radioactive cesium decontaminator, and a method of removing radioactive cesium using the decontaminator. The radioactive cesium decontaminator is formed by agglomeration of primary particles. The primary particles have a magnetic particle as a core portion, a coating layer made of an organic material coating the magnetic particle, and a capturing compound made of ferrocyanide material formed on the coating layer. A cumulative diameter D50 of the decontaminator is in a range of from 2.0 ?m to 50 ?m, and a value of a cumulative diameter distribution (D90?D10)/D50 is less than 6. The decontaminator is made by adding a ferrocyanide aqueous solution and an aqueous solution containing at least one transition metal into a suspension liquid containing a precursor formed by magnetic particles coated with organic monomer or polymer while applying a strong shear force.

Abstract: The present invention provides an artificial kidney precursor containing a non-human mammalian metanephros separated out from a living body, wherein the metanephros has been subjected to freezing and thawing treatments outside a living body, and contains mammalian mesenchymal stem cells transferred outside a living body, and a method of production thereof.

Abstract: There is provided an aggregate of radioactive material removing particles in which two or more radioactive material removing particles having magnetic particles and a radioactive material adsorption component are assembled, wherein a pore volume in the aggregate is 0.5 mL/g or more and 5.0 mL/g or less, and the pore volume means a cumulative value obtained by a mercury press-in method.

Abstract: A novel vaccine that can induce sufficiently high cell-mediated immunity is disclosed. The vaccine of the present invention contains, as an effective component, a polypeptide comprising a tandem repeat structure in which an MHC class I epitope region derived from an antigen protein and a spacer sequence are linked to each other alternately and repeatedly at least three times, or a recombinant vector which comprises a polynucleotide encoding said polypeptide and is capable of expressing said polypeptide in vivo. The spacer sequence is, for example, a sequence generated as an amino acid sequence inevitably encoded by a single base sequence which is designed such that the MHC class I epitope region derived from the antigen protein, an MHC class II epitope region derived from the antigen protein, and at least one higher-order-structure-stabilizing region are encoded by different reading frames in said single base sequence.

Abstract: There is provided a method of producing a radioactive cesium decontaminator, including: suspending magnetic particles in a solvent, and coating each magnetic particle with organic monomer or polymer, to thereby form a precursor; adding a ferrocyanide aqueous solution and an aqueous solution containing at least one kind of transition metal into a suspension liquid containing the precursor after coating while applying a strong shear force, to thereby generate a radioactive cesium decontaminator; and removing water content from a slurry containing the obtained radioactive cesium decontaminator.

Abstract: The present invention provides an artificial kidney precursor containing a non-human mammalian metanephros separated out from a living body, wherein the metanephros has been subjected to freezing and thawing treatments outside a living body, and contains mammalian mesenchymal stem cells transferred outside a living body, and a method of production thereof.